Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor-Reference-Cited by-同舟云学术

Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor

Published:2012-03 Issue:1 Volume:350 Page:99-106
ISSN:0303-7207
Container-title:Molecular and Cellular Endocrinology
language:en
Short-container-title:Molecular and Cellular Endocrinology

Author:

Iida Shinya,Miki Yasuhiro,Ono Katsuhiko,Akahira Jun-ichi,Nakamura Yasuhiro,Suzuki Takashi,Sasano Hironobu

Publisher

Elsevier BV

Subject

Endocrinology,Molecular Biology,Biochemistry

Reference54 articles.

1. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer;Amato;Cancer,2009

2. Treatment of neuroendocrine GEP tumours with somatostatin analogues;Arnold;Digestion,2000

3. The TOR pathway: a target for cancer therapy;Bjornsti;Nat. Rev. Cancer,2004

4. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer;Carracedo;J. Clin. Invest.,2008

5. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors;Chan;Adv. Ther.,2010

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets;Cancers;2021-10-12

2. Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro;Cancers;2021-03-23

3. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature;Endocrine-Related Cancer;2018-06

4. mTOR complexes differentially orchestrates eosinophil development in allergy;Scientific Reports;2018-05-02

5. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors;Endocrine-Related Cancer;2018-05